A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. We were originally incorporated in 1998 under the name of Optis France S.A. in Paris, France. We were formed as a Delaware corporation on December 28, 2004, under the name of EyeGate Pharmaceuticals, Inc., and changed our name to Kiora Pharmaceuticals, Inc. effective November 8, 2021 in connection with a merger of one of our wholly owned subsidiaries. We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP"). KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP.
| Metric | TTM | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 16M | 0 | 0 | - | - |
| Net Income | -8.5M | 3.6M | - | -14M | -6.9M | -7.1M |
| EPS | $-2.08 | $0.87 | $-24.25 | $-514.80 | $-536.40 | $-802.80 |
| Free Cash Flow | 0 | 8.6M | -9.6M | -11M | -7.3M | -8.2M |
| ROIC | -210.4% | 11.1% | - | -92.7% | -68.6% | -54.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.42 | 1.24 | 0.03 | 0.07 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -8.1M | 4.5M | -13M | -14M | -6.9M | -7.0M |
| Operating Margin | 0.0% | 28.2% | - | - | - | - |
| ROE | -38.1% | 22.6% | - | -113.3% | -70.5% | -107.2% |
| Shares Outstanding | 4M | 4M | 3M | 0M | 0M | 0M |
KIORA PHARMACEUTICALS INC passes 2 of 9 quality checks, indicating weak fundamentals.
KIORA PHARMACEUTICALS INC trades at 2.8x trailing earnings, compared to its 15-year median P/E of 3.8x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 1.2x vs a median of 1.6x. At current prices, the estimated annualized return to fair value is +36.2%.
KIORA PHARMACEUTICALS INC (KPRX) has a current P/E ratio of 2.8, compared to its historical median P/E of 3.8. The stock is currently considered Cheap based on its historical valuation range.
KIORA PHARMACEUTICALS INC (KPRX) has a 5-year average return on invested capital (ROIC) of -51.2%. This is below average and may indicate limited pricing power.
KIORA PHARMACEUTICALS INC (KPRX) has a market capitalization of $9M. It is classified as a small-cap stock.
KIORA PHARMACEUTICALS INC (KPRX) does not currently pay a regular dividend.
Based on historical P/E analysis, KIORA PHARMACEUTICALS INC (KPRX) appears cheap. The current P/E of 2.8 is 26% below its historical median of 3.8.
KIORA PHARMACEUTICALS INC (KPRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
KIORA PHARMACEUTICALS INC (KPRX) reported annual revenue of $16 million in its most recent fiscal year, based on SEC EDGAR filings.
KIORA PHARMACEUTICALS INC (KPRX) has a net profit margin of 22.4%. This is a strong margin indicating high profitability.
KIORA PHARMACEUTICALS INC (KPRX) generated $9 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
KIORA PHARMACEUTICALS INC (KPRX) has a debt-to-equity ratio of 0.42. This indicates a conservatively financed balance sheet.
KIORA PHARMACEUTICALS INC (KPRX) reported earnings per share (EPS) of $0.87 in its most recent fiscal year.
KIORA PHARMACEUTICALS INC (KPRX) has a return on equity (ROE) of 22.6%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 10 years of financial data for KIORA PHARMACEUTICALS INC (KPRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
KIORA PHARMACEUTICALS INC (KPRX) has a book value per share of $6.23, based on its most recent annual SEC filing.